

TheraCryf plc
("TheraCryf", the "Company" or the "Group")

Update on integration of acquired company Chronos Therapeutics Limited

Alderley Park, 2 May 2024 - TheraCryf plc (AIM:TCF), formerly Evgen Pharma plc, the clinical stage drug development company focussing on oncology and neuropsychiatry, provides an update on the integration of Chronos Therapeutics Ltd (Chronos) further to the announcements on 19th March and 25th April 2024. This update follows the acquisition, accompanying placing and results of the Company's general meeting approving the issuance of shares and, as of 25 April 2024, the change of name to TheraCryf plc and the AIM ticker to TCF.

The following actions have taken place to date:

- Transaction effective from 5 April 2024
- Former Chronos shareholders received 62'291'778 shares as the first consideration
- Transition of Chronos to a wholly owned affiliate of TheraCryf complete
- Board members of Chronos stepped down as pre-agreed
- Toni Haenninen and Dr Huw Jones appointed directors of Chronos effective 19 April 2024
- Email and website (www.theracryf.com) transition complete
- Transfer of records, technical study reports and financial systems well advanced

Dr Huw Jones, CEO of TheraCryf, said

"Many thanks to the TheraCryf team for executing the transition in a speedy and efficient way. I would also like to thank the members of the board of Chronos for their important part in the transaction and the transition of Chronos to become part of the TheraCryf Group.

"We strongly believe that having additional scale and a broadened pipeline of development programmes will enhance shareholder value considerably. We are focussed on our entire portfolio, comprising our SFX-01 programme in glioblastoma and autism, our Orexin-1 antagonist in impulsivity and addiction, and our atypical DAT inhibitor in fatigue and narcolepsy. In common with the non-dilutive funding already in place for SFX-01 in glioblastoma, we are actively seeking non-dilutive funding for our acquired programmes."

- Ends -

Enquiries

TheraCryf plc

Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO

+44 (0)1625 315 090
enquiries@theracryf.com

Cavendish Capital Markets (NOMAD and Broker)

Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)

+44 20 7220 0500

Instinctif Partners

Melanie Toyne-Sewell / Jack Kincade

+44 207 457 2020
theracryf@Instinctif.com

About TheraCryf plc

TheraCryf plc (formerly known as Evgen plc) is a clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications such as neurodevelopmental disorders, glioblastoma*, addiction, anxiety and narcolepsy* [*orphan indications].

The Company's lead clinical asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and most recently, a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands funded via a grant from the Netherlands government to the Erasmus Medical centre, Rotterdam.

In April 2024, TheraCryf acquired neuropsychiatry company, Chronos Therapeutics Limited. The acquired assets comprise an orexin-1 antagonist

(Ox-1) in late pre-clinical development targeting impulsivity and anxiety disorders and an atypical dopamine transporter inhibitor (DAT) also in late pre-clinical development for fatigue, e.g. due to long COVID or multiple sclerosis and the orphan condition narcolepsy.

The Company's strategy is to generate compelling data sets to proof of concept and/or later phase II to partner its clinical programmes with mid-size to large pharma. As well as a number of industry partnerships with companies, including Stalicia, in neurodevelopment disorders and has sourced programmes from companies such as Takeda and Shire, the Company has worked with and has ongoing collaborations with major universities, hospitals and government organisations such as the University of Manchester, Sapienza (Università di Roma), Kings College London and University of Connecticut.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF.

For further information, please visit: www.theracryf.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEAPSFDNLEFA